This peer-reviewed article from interdisciplinary experts describes the impact of the IMbrave150 trial on treating advanced hepatocellular carcinoma.


The HCC Experts Round Table (Americas & Europe) brought together international experts in hepatocellular carcinoma, from fields including oncology, hepatology, radiology, patient advocacy, and health economics. The HCC Experts Round Table has recently published their assessment of the impact of the IMbrave150 trial on standards of care for advanced first-line HCC.

Watch the video overview from manuscript senior author Prof. Peter Galle and download your educational slides, summarizing the conclusions of the HCC Experts Round Table in their peer-reviewed publication. This educational content is relevant for all clinical team members involved in the care of advanced HCC.

Kulik L, da Fonseca LG, He AR, Rimola J, Wilson Woods A, Zöllner YF, Galle PR. Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion. J Hepatocell Carcinoma. 2020;7:423

This programme is supported by an Independent Educational Grant from Roche.

Hello, my name is Peter Galle, from the University Medical Center in Mainz, Germany. Last year, a multidisciplinary team of experts convened to discuss the impact of the IMbrave150 trial, assessing the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

This resulted in a position paper, where we discuss the important aspects of the trial with respect to efficacy, safety, and the impact on scheduling of systemic therapy in hepatocellular carcinoma.

We are now at a situation where we have seen a timely update of the data from 2020, which appeared at the ASCO GI meeting in January 2021 in San Francisco. It was good to see that the improvement of overall survival (OS) was not only confirmed, but now it was actually given in absolute numbers: we see a six-month improvement in overall survival comparing atezo + bev versus sorafenib.

This has resulted in the meantime in the approval of this combination in more than 160 countries worldwide, for the benefit of our patients. Thank you for your interest.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Roche
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

GI-oncology-GI-CONNECT-10-years-thumbnail-GI2403 Video
Oncology 
Celebrating the 10th anniversary of GI CONNECT

10 years of independent medical education in GI oncology

Experts
Assoc. Prof. Gerald Prager, Assoc. Prof. Joleen Hubbard, Dr Thomas Winder, Prof. Andrea Sartore-Bianchi, Dr Dominik Modest
  • clock 2 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer